• Everest Medicines posted IFRS revenue of RMB 1.15 billion, more than doubled from a year earlier.
• Net loss attributable to equity holders narrowed to RMB 5.9 million, from RMB 249.8 million.
• Gross margin rose 2.5 percentage points to 69.6%.
• Operating loss shrank to RMB 32.6 million, from RMB 262.6 million.
• Non-IFRS adjusted profit turned to RMB 97.2 million, from an adjusted loss of RMB 146.9 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Medicines Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260819-12289548), on August 18, 2026, and is solely responsible for the information contained therein.